Hypoparatyhroidism Treatment

There is no cure for hypoparathyroidism

Treatment aims to eliminate symptoms (to the extent possible) while simultaneously protecting the kidneys and other organs. This involves careful monitoring of blood work and requires patients, their families, and their caregivers to be compliant and diligent with managing their care.


The most common hypoparathyroidism treatment options are: 



Do you have more questions about hypoparathyroidism?

Check out our FAQs and our resource library to strengthen your understanding and get additional support.


Calcium Supplementation

There are two main types of calcium supplements; carbonate and citrate. There are numerous brands and forms of calcium available, including powders, pills, liquids, and chewables, and they all come in different strengths. What works for one person may not work for another, so it is important that patients work with their medical providers to find their most optimal calcium supplementation.


Calcitriol (also called Rocaltrol) 

Calcitriol is the active form of Vitamin D. In the absence of PTH, the kidneys do not convert Vitamin D to its active form. Because of this, most patients need to take an active form of vitamin D, available via prescription, in addition to calcium. This helps the calcium coming in through supplementation and diet to absorb into the bloodstream properly. 


Vitamin D

Vitamin D (the native form, before it has been converted to calcitriol) plays an important role in the absorption of calcium from food in the intestines. Many people in the United States have low Vitamin D levels. People with hypoparathyroidism may struggle to maintain Vitamin D. Supplementing with Vitamin D is sometimes necessary, in addition to calcitriol.  


Sometimes the kidneys release too much calcium. Thiazides (known as diuretics) can be used to help kidneys reabsorb calcium when needed.




In 2015, Natpara, the only FDA-approved full parathyroid hormone molecule (1-84), became available for patients who were not adequately managed on supplementation. Natpara was recalled in September 2019 due to a defect in the delivery mechanism. Natpara is currently only available in the United States to people approved through the Special Use Program.


Forteo is a partial PTH molecule (1-34) that is FDA approved for Osteoporosis. It has been clinically studied for use with hypoparathyroidism, and some people are using Forteo in an off-label manner. Forteo is an injectable medication that requires close monitoring. 

Others in Development 

There are currently a few other medications undergoing clinical trials. These new medications should expand treatment options. Hypopara patients are invited to participate, where able, in clinical trials. Click here to learn more.